LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced preliminary …
Author: Business Wire
Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO…
OcuTerra Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics announces President and CEO Kerrie Brady will present at the J.P. Morgan Healthcare Conference in San Francisco on January 11.
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced advancement of its RA…
LumiThera ofrece información actualizada sobre la revisión de la FDA del tratamiento Valeda para pacientes con DMAE seca
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., una empresa de dispositivos médicos que ofrece un tratamiento de fotobiomodulación para enfermedades y daños oculares, ha dado hoy a conocer nuevos datos sobre el estado reglamentario del sistema Valeda® Light …
LumiThera geeft update over FDA-beoordeling van Valeda-behandeling voor patiënten met droge AMD
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., een bedrijf gespecialiseerd in medische apparatuur dat PBM-behandeling (fotobiomodulatie) aanbiedt voor oogschade en oogaandoeningen, maakte vandaag een update bekend over de wettelijke status van het Valeda® L…
LumiThera gibt aktuellen Stand der FDA-Prüfung der Valeda-Behandlung für Patienten mit trockener AMD bekannt
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., ein Medizintechnikunternehmen, das Photobiomodulation (PBM) zur Behandlung von Augenschäden und -erkrankungen anbietet, gab heute ein Update zum Zulassungsstatus des Valeda® Light Delivery System bekannt. Nach …
LumiThera offre un aggiornamento sulla valutazione da parte dell'FDA del trattamento Valeda per i pazienti affetti da degenerazione maculare senile (DMS)
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., azienda di dispositivi medici che offre trattamenti di fotobiomodulazione (PBM) per danni e malattie oculari, ha annunciato oggi un aggiornamento sullo stato normativo del Valeda® Light Delivery System. A segui…
LumiThera fait une mise à jour de l'examen sur le traitement du Valeda par la FDA pour les patients atteints de DMLA sèche
SEATTLE–(BUSINESS WIRE)–LumiThera Inc. est une entreprise de dispositifs médicaux qui propose un traitement des lésions et des maladies oculaires par photobiomodulation (PBM) a annoncé aujourd’hui une mise à jour du statut réglementaire du système de…
Melt Pharmaceuticals Provides Corporate Update
NASHVILLE, Tenn.–(BUSINESS WIRE)–Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update. The Company previously announced that MELT-300 achie…
LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients
Harrow Partners with Leading Healthcare Market Access Technology Platforms
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE® (cyclospor…
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
GENEVA–(BUSINESS WIRE)–Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
GENEVA–(BUSINESS WIRE)–Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001
TOKYO–(BUSINESS WIRE)–Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a deep tech start-up developing a novel cell therapy, announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to our reg…
Weave Named a 2023 Top Workplace USA
LEHI, Utah–(BUSINESS WIRE)–Weave (NYSE: WEAV), a leading all-in-one experience platform for small and medium-sized healthcare practices, has earned designation as a 2023 Top Workplaces USA and 2023 Top Workplaces Utah. In addition to the 2023 Top Wor…
Marshall B. Ketchum University Celebrates 2023 Health Care Education Achievements and Innovations
FULLERTON, Calif.–(BUSINESS WIRE)–Marshall B. Ketchum University (MBKU), an independent, private, non-profit, accredited educational institution in Fullerton, California is grateful for a transformative year and proudly reflects on unprecedented succ…
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
ECM Therapeutics Announces Collaboration with the Louis J. Fox Center at the University of Pittsburgh Vision Institute to Advance Cutting-edge Technology for Optic Nerve Repair
PITTSBURGH–(BUSINESS WIRE)–ECM Therapeutics and Louis J. Fox Center at the University of Pittsburgh collaborate to advance cutting-edge technology for optic nerve repair
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line res…